false
0001642380
0001642380
2024-06-17
2024-06-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (date of earliest event reported): June 17, 2024
Oncocyte
Corporation
(Exact
name of registrant as specified in its charter)
California |
|
1-37648 |
|
27-1041563 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
15
Cushing
Irvine,
California 92618
(Address
of principal executive offices)
(949)
409-7600
(Registrant’s
telephone number, including area code)
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, no par value |
|
OCX |
|
The
Nasdaq Stock Market LLC |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
June 17, 2024, the Board of Directors (the “Board”) of Oncocyte Corporation (the “Company”) appointed Andrea
James to serve as the Company’s Chief Financial Officer, effective June 17, 2024. Ms. James will also serve as the Company’s
Principal Financial Officer. James Liu will continue to serve as the Company’s Senior Director, Controller & Principal Accounting
Officer.
Ms.
James joined Axon Enterprise in September 2017 as Vice President of Investor Relations. In May 2019, she was promoted to Vice President
of Corporate Strategy & Investor Relations. In July 2020, she was promoted to Senior Vice President of Corporate Strategy & Investor
Relations. In September 2022, she was promoted to Chief Communications Officer, reporting to the chief financial officer and maintaining
her responsibility for investor relations. Ms. James concluded full-time employment at Axon on December 31, 2023 and continued to work
as an advisor to Axon through May 2024, to ensure a smooth transition. Previously, Ms. James consulted in a strategic investor relations
role for Tesla, Inc., and served as a vice president and senior research analyst for Dougherty & Company (now Colliers Securities),
an investment bank, where she researched emerging technologies on behalf of institutional investors. Ms. James holds a B.S. in Computer
Information Systems from American University, with a dual-minor in Applied Physics and Communications. She holds an M.S. in Journalism
from Northwestern University.
In
connection with Ms. James appointment as Chief Financial Officer, Ms. James entered into an employment agreement with the Company (the
“Employment Agreement”), effective June 17, 2024. Pursuant to the terms of the Employment Agreement, Ms. James will receive
an initial annual base salary of $325,000 (such annual base salary, as may be adjusted by the Board from time to time, the “Base
Salary”) and will be eligible to receive an initial annual cash bonus, targeted at 50% of the Base Salary (such target, as may
be adjusted by the Board from time to time, the “Annual Bonus”).
If
Ms. James’s employment is terminated by the Company without Cause (as defined in the Employment Agreement), or Ms. James resigns
from the Company with Good Reason (as defined in the Employment Agreement), the Company shall: (a) pay Ms. James all accrued but unpaid
Base Salary and any vacation or paid time off accrued, (b) any vested benefits to which Ms. James or her estate may be entitled to under
the Company’s benefit plan’s or applicable law, (c) an amount equal to 12-months of the Base Salary, (d) pay Ms. James an
amount equal to a pro-rated portion of the Annual Bonus, (d) reimbursement for an amount equal to the monthly portion of the premium
cost of participation in such group health plan that the Company paid for immediately prior to the date of termination for a period of
up to 12 months, (e) with respect to each outstanding time-based equity award, if any, accelerated vesting of the next trench of time-based
equity that would have vested had Ms. James remained employed through the next applicable vesting date, and (f) with respect to the Performance
Equity Award (as defined below), accelerated time vesting of any options that are performance vested as of the date of termination.
The
foregoing description of the Employment Agreement does not purport to be complete and is subject to and qualified in its entirety by
reference to the full and complete text of the Employment Agreement, attached as an exhibit to the Company’s Quarterly Report on
Form 10-Q for the period ending June 30, 2024.
Additionally,
in connection with Ms. James’ appointment as Chief Financial Officer, the Board approved the following grants to Ms. James: (a)
an Option (as defined in the Company’s 2018 Equity Incentive Plan (the “Plan”)) to purchase 200,000 shares of the Company’s
common stock, no par value (“Common Stock”)(the “Stock Option Grant”), and (b) an award of 100,000 Restricted
Stock Units (as defined in the Plan)(the “Performance Equity Grant”). Both the Stock Option Grant and the Performance Equity
Grant shall be made subject to shareholder approval of an amendment to the Plan, increasing the total number of shares of Common Stock
available for grant of awards under the Plan.
Ms.
James has no family relationships with any director or executive officer of the Company. There are no arrangements or understandings
between Ms. James and any other person pursuant to which Ms. James was appointed as an executive officer. Additionally, there are no
transactions involving Ms. James that would require disclosure under Item 404(a) of Regulation S-K.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
ONCOCYTE
CORPORATION |
|
|
Date:
June 17, 2024 |
By:
|
/s/
Joshua Riggs |
|
|
Joshua
Riggs |
|
|
President
and Chief Executive Officer |
Exhibit
99.1
Oncocyte
Appoints Andrea James as Chief Financial Officer
IRVINE,
Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq:
OCX), a precision diagnostics company, today announced that it has appointed leading finance executive, Andrea James, to the position
of Chief Financial Officer.
“We
are thrilled to welcome Andrea as we approach the inflection point of commercial launch,” Oncocyte CEO Josh Riggs said. “She has a proven track record of guiding financial strategy through
multiple phases of growth, raising and stewarding capital, and building relationships with high quality institutional investors. Andrea
is therefore an ideal CFO business partner to myself, the Board of Directors and the Oncocyte team.
“We
expect 2024 and 2025 to be transformative years for Oncocyte. We have begun to establish our diagnostic tests as the research tool of
choice for the transplant community together with our co-marketing partner Bio-Rad Laboratories (NYSE:BIO). Separately, we also
see the opportunity to unlock high-value clinical diagnostic opportunities in the oncology space, and add to our commercialization partnerships.
We eagerly anticipate Andrea’s valuable insights as we continue to drive value creation for Oncocyte’s shareholders.”
Prior
to joining Oncocyte, Ms. James served as Chief Communications Officer and head of investor relations at Axon Enterprise, Inc. (Nasdaq:
AXON). She joined Axon’s finance team in 2017 to build the company’s investor relations function and played an integral role
through the company’s growth from $1 billion in market capitalization to a company valued at more than $20 billion. She led Axon’s
repositioning as a top-tier technology company with the investment community and established Axon’s corporate strategy function,
overseeing capital stewardship, mergers and acquisitions, strategic partnerships and investments. Her work was instrumental in supporting
more than $550 million in equity capital offerings.
Ms.
James worked in a strategic investor relations role for Tesla, Inc. (Nasdaq: TSLA) in 2016 and 2017. From 2009 to 2016 she worked as
a sell-side analyst for Dougherty & Company (now Colliers Securities), becoming a vice president and senior research analyst. At
Dougherty, she researched emerging technologies on behalf of institutional investors. Previously, she was a reporter at publications
including Bloomberg News and the Seattle Post-Intelligencer covering a range of business and financial beats.
“Oncocyte
is a disruptive innovator in the field of molecular diagnostics that is on track for category leadership. The company enjoys a top-notch
management team with extensive experience in this space,” Ms. James said. “I am delighted to join and look forward to helping
to scale the company into a much larger, highly profitable enterprise over time, while also ensuring that the capital markets understand
our exciting runway and global market opportunity.”
“I
also want to commend James Liu, who has served as Oncocyte’s controller and principal accounting officer and who will continue
to serve as an important leader within our finance team,” James added.
Ms.
James holds a Bachelor of Science, summa cum laude, in Computer Information Systems from American University. She also holds a
Master of Science in Journalism from Northwestern University, graduating with Kappa Tau Alpha honors. While at Dougherty, her Financial
Industry Regulatory Authority (FINRA) licenses included the Series 7, 86, 87 and 63.
About
Oncocyte
Oncocyte
is a precision diagnostics company. The Company’s tests are designed to help provide clarity and confidence to physicians and their
patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use
only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor
microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic
efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about
our products, please visit the following web pages:
VitaGraft
Kidney™ - https://oncocyte.com/vitagraft-kidney/
VitaGraft
Liver™ - https://oncocyte.com/vitagraft-liver/
GraftAssure™
- https://oncocyte.com/graftassure/
DetermaIO™
- https://oncocyte.com/determa-io/
DetermaCNI™
- https://oncocyte.com/determa-cni/
VitaGraft™,
GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.
Forward-Looking
Statements
Any
statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,”
“plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions)
are forward-looking statements. These statements include those pertaining to, among other things, Oncocyte’s ongoing commercialization
efforts and Ms. James’ expected contributions to the Company, and other statements about the future expectations, beliefs, goals,
plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation,
risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials
or regulatory approvals, the capacity of Oncocyte’s third-party supplied blood sample analytic system to provide consistent and
precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital,
maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or
acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Oncocyte
or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure
to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls,
potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain
any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking
statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte,
particularly those mentioned in the “Risk Factors” and other cautionary statements found in Oncocyte’s Securities and
Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
CONTACT:
Jeff
Ramson
PCG
Advisory
(646)
863-6893
jramson@pcgadvisory.com
v3.24.1.1.u2
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Oncocyte (NASDAQ:OCX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024